Search

A 63-year-old man with multiple comorbidities developed drug-induced subacute cutaneous lupus erythematosus (SCLE) while being treated with dupilumab for chronic hand dermatitis, after showing lack of efficacy with clobetasol. Despite trying various treatments like crisaborole, tacrolimus, and methotrexate, his symptoms only partially improved. Upon starting dupilumab, his symptoms improved, but he later developed SCLE, leading to discontinuation of the medication. The man's truncal eruption resolved after stopping dupilumab, but he experienced persistent dry mouth and tongue discomfort, requiring further assessment by a rheumatologist. [Extracted from the article]

A 70-year-old woman developed thyroid dysfunction, bullous pemphigoid, and diarrhea while undergoing treatment with pembrolizumab for gastric mucosal melanoma. The woman experienced hypothyroidism four months after starting pembrolizumab, which was successfully managed with thyroid hormone medication. Subsequently, she developed bullous pemphigoid, leading to the discontinuation of pembrolizumab and initiation of prednisolone treatment. Despite these adverse reactions, the woman's lung metastasis did not worsen six months after stopping pembrolizumab. [Extracted from the article]

The article discusses two case reports of patients, a 12-year-old girl and a 16-year-old boy, who developed urticaria during treatment with naxitamab for stage M neuroblastoma. Both patients also experienced lack of efficacy with traditional treatments for urticaria. The girl's urticaria was successfully managed with off-label treatment using omalizumab, while the boy required omalizumab to resolve his urticaria and continue his chemoimmunotherapy. The patients' responses to treatment were closely monitored, and they were able to complete their therapy cycles successfully. [Extracted from the article]

A man in his late 30s developed drug-induced immune thrombocytopenia (DITP) while being treated with ceftriaxone for miliary tuberculosis caused by Mycobacterium tuberculosis. Initially, DITP was suspected due to rifampicin, but further testing confirmed ceftriaxone as the cause. After discontinuing ceftriaxone and switching to a different treatment regimen, the patient's platelet count began to recover. The case highlights the importance of identifying and managing drug-induced immune reactions in patients with complex medical histories. [Extracted from the article]

A 67-year-old man developed diabetes ketoacidosis (DKA) due to diabetes mellitus while being treated with pembrolizumab for metastatic cancer of unknown primary site (CUP). He had a history of alcohol use disorder, alcohol-associated cirrhosis, hypertension, and atrial fibrillation. After presenting with symptoms of nausea and vomiting, he was found to be hyperglycemic and was admitted to the ICU for the management of DKA. Treatment with insulin and fluids led to the complete resolution of DKA, and he was discharged without any complications. [Extracted from the article]

The article describes five cases of patients, three men and two women aged 74-88, who experienced lack of efficacy while being treated with avacopan for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. One patient also exhibited a rebound effect in the form of microscopic polyangiitis (MPA) symptoms flaring after a reduction in prednisolone dosage. Despite treatment with avacopan, the patients' conditions did not improve, leading to discontinuation of avacopan and alternative treatments to induce remission. [Extracted from the article]

A 46-year-old man with a history of hypertension and uncontrolled type 2 diabetes mellitus developed external insulin antibody syndrome (EIAS) while being treated with insulin for diabetic ketoacidosis (DKA). Despite receiving immune globulin treatment for EIAS, he did not show any improvement. The man was eventually diagnosed with EIAS secondary to insulin and received mycophenolate mofetil, which temporarily normalized his blood sugar levels and improved his EIAS. Long-acting insulin infusion was restarted, and he was referred for further management. [Extracted from the article]

A 38-year-old man with thymoma-associated generalised myasthenia gravis exhibited a lack of efficacy during treatment with tacrolimus and ciclosporin. After receiving two cycles of antineoplastics and a thymectomy, his condition initially improved with prednisolone but worsened three months later, leading to myasthenic crisis. Immune-globulin and methylprednisolone were effective in treating the crisis, but tacrolimus and ciclosporin proved ineffective. Plasma exchange and efgartigimod-alfa were subsequently used, resulting in improvement and a decrease in symptoms. [Extracted from the article]

A 53-year-old man developed myasthenia gravis after receiving the AZD-1222 vaccine for COVID-19. He experienced symptoms such as diplopia and abduction paresis in his right eye one day after the first dose, followed by ptosis in both eyes two weeks later. Initially, it was thought to be cranial neuropathy, but he was eventually diagnosed with myasthenia gravis. Treatment with dexamethasone, vitamin-B-complex, pyridostigmine, prednisolone, and immune-globulin resulted in improvement of his condition. Serology examination showed elevated anti-AChR antibody titer in his serum. [Extracted from the article]

A 48-year-old man developed lichen planus of the penis while being treated with nebivolol for arterial hypertension. The man presented with whitish spots on the skin of the penis, which were partially responsive to initial treatments. Further examinations revealed specific dermatological findings and laboratory results that led to the conclusion that the lichen planus was caused by nebivolol. After discontinuing nebivolol, the man's condition improved with alternative medications. [Extracted from the article]

A 49-year-old woman with moderate-to-severe chronic plaque psoriasis experienced latent tuberculosis (LTBI) reactivation while being treated with ustekinumab. She also showed lack of efficacy when treated with acitretin. The woman initially started ustekinumab in 2013 and achieved a psoriasis area severity index (PASI) score of zero at week 12. In 2017, she developed a malar rash and positive antinuclear antibody test, leading to the suspicion of lupus as a potential adverse effect. Ustekinumab was temporarily stopped and restarted after ruling out lupus. However, a repeat QuantiFERON test showed a positive result, leading to the diagnosis of LTBI reactivation due to ustekinumab. The medication was stopped, and the woman was treated for LTBI. Ustekinumab was later restarted, but had to be stopped again in 2020 due to the COVID-19 pandemic. Acitretin was then used as an alternative, but the woman experienced worsening of her condition, indicating lack of efficacy. She eventually resumed ustekinumab in 2021, but the outcome of the adverse drug reaction was not stated. [Extracted from the article]

An 81-year-old woman developed a non-severe immune-mediated necrotising myopathy (IMNM) while being treated with pitavastatin for dyslipidaemia. She later developed mild diabetes mellitus while being treated with prednisolone for the IMNM. The woman experienced progressive gait instability and muscle weakness, and her laboratory tests revealed elevated levels of creatine kinase and haemoglobin A1c. Pitavastatin was discontinued, and she was treated with methylprednisolone, immune-globulin, and tacrolimus, which resulted in an improvement in the IMNM. However, she developed mild diabetes mellitus as a side effect of the prednisolone, which was managed with medication. The IMNM completely resolved, and there was no recurrence after tapering off the prednisolone. [Extracted from the article]

A 77-year-old woman with relapsing-remitting multiple sclerosis (RRMS) developed gastrointestinal bleeding while being treated with methylprednisolone. She had a history of idiopathic cardiomyopathy and watermelon stomach and presented with diplopia and hemiparesis. After being diagnosed with very late onset RRMS, she started treatment with IV methylprednisolone but experienced GI bleeding as a side effect. Her treatment with methylprednisolone was stopped, and she was subsequently considered for second-line treatment with natalizumab and later rituximab. Despite the change in treatment, her disability status remained stable during the follow-up period. [Extracted from the article]

In an observational study, two patients between the ages of 11 and 18 experienced a lack of efficacy when treated with the tozinameran vaccine for COVID-19. The first patient, an 11-year-old boy with a kidney condition, received the vaccine but did not develop protective antibodies and later contracted COVID-19 with mild symptoms. The second patient, an 18-year-old woman with a genetic disorder, also did not develop protective antibodies after receiving the vaccine and later contracted COVID-19 with mild symptoms. The lack of efficacy was attributed to the tozinameran vaccine in both cases. [Extracted from the article]

A 40-year-old woman with type 1 diabetes mellitus developed an allergy to insulin and various insulin medications. She experienced skin reactions at the injection sites, including erythema, wheals, and lipodystrophy. After testing positive for insulin-specific IgG antibodies and receiving a skin biopsy, she was diagnosed with insulin allergy. The woman was treated with metformin, dapagliflozin, and liraglutide, but her skin reactions only improved after receiving rituximab. The effects of rituximab lasted for 18 months after the first round of treatment and have been prolonged with no recurrent skin reactions up to 4 years later. [Extracted from the article]

A 15-year-old boy with epilepsia partialis continua (EPC) exhibited lack of efficacy with multiple drugs, including felbamate, eslicarbazepine acetate, phenobarbital, and clonazepam. After undergoing brain surgery and experiencing complications such as anti-Hu limbic encephalitis and mediastinal seminoma, the boy received valproic acid, lacosamide, perampanel, and clobazam, which improved his symptoms. However, his condition eventually deteriorated, and he did not respond to additional medications such as felbamate, eslicarbazepine acetate, phenobarbital, and clonazepam. Ultimately, he underwent a hemispherectomy, which resolved his EPC. [Extracted from the article]

A 39-year-old woman with pemphigus vulgaris experienced a lack of efficacy while being treated with prednisolone during her pregnancy. She also received immune-globulin and methylprednisolone for the same condition. Despite taking prednisolone, her rash did not improve, so she was given IV methylprednisolone, which partially improved her symptoms. At 24 weeks gestation, she started receiving IV immune-globulin, which led to further improvement. She delivered a healthy baby via caesarean section at 37 weeks gestation and continued to experience improvement after giving birth. [Extracted from the article]

A 57-year-old man developed insulin autoimmune syndrome while being treated with carbimazole for hyperthyroidism. He experienced symptoms such as syncope, palpitations, hand tremors, sweating, and unintentional weight loss. The man had a history of hyperthyroidism and was non-adherent to his carbimazole treatment. He was diagnosed with insulin autoimmune syndrome based on his symptoms and test results, and was treated with acarbose. After treatment, his glucose levels stabilized and he was discharged. Upon restarting carbimazole, his anti-TSH receptor antibody levels decreased and he did not experience any further episodes of hypoglycemia. [Extracted from the article]

A 59-year-old woman experienced enteropathy while being treated with olmesartan-medoxomil for hypertension. She was admitted to the hospital with symptoms of diarrhea, abdominal pain, and vomiting after starting the antihypertensive medication. Despite extensive testing, the cause of her chronic diarrhea was not identified, but biopsies revealed inflammation in her stomach and small intestine. The enteropathy was determined to be a result of the olmesartan-medoxomil treatment. After discontinuing the medication, her symptoms improved and her intestinal mucosa returned to normal. [Extracted from the article]

A 59-year-old woman experienced enteropathy while being treated with olmesartan-medoxomil for hypertension. She was admitted to the hospital with symptoms of diarrhea, abdominal pain, and vomiting after starting the antihypertensive medication. Despite extensive testing, the cause of her chronic diarrhea was not identified, but biopsies revealed inflammation in her stomach and small intestine. The enteropathy was determined to be a result of the olmesartan-medoxomil treatment. After discontinuing the medication, her symptoms improved and her intestinal mucosa returned to normal. [Extracted from the article]

A 33-year-old woman with pemphigoid gestationis (PG) received prednisone during her first pregnancy, which resulted in a healthy baby. However, during her second pregnancy at the age of 36, she experienced lack of efficacy with various medications including cetirizine, clobetasol, diphenhydramine, triamcinolone, hydrocortisone, and prednisone. She was diagnosed with PG again and received oral prednisone, but it did not improve her symptoms. She was then treated with dupilumab, which led to an improvement in her rash, blisters, and itching. She delivered a healthy baby and continued to resolve her PG with dupilumab after giving birth. [Extracted from the article]

A 48-year-old woman with follicular lymphoma developed drug-induced organizing pneumonia, hypogammaglobinemia, and myelosuppression during treatment with rituximab, bendamustine, and prednisolone. She was initially diagnosed with drug-induced organizing pneumonia and received steroid therapy. After being discharged, she tested positive for SARS-CoV-2 and was hospitalized, but later discharged due to stable vital signs. Fifty days later, she developed new pneumonia and her SARS-CoV-2 test was positive again. She was treated with convalescent plasma and her condition improved after receiving immune-globulin therapy. She was eventually discharged and remained stable at the outpatient clinic. [Extracted from the article]

A 39-year-old man experienced a suppressed neutralizing antibody response while being treated with prednisone for severe asthma. After receiving the smallpox vaccine for immunization against monkeypox, he showed a lack of efficacy. The man had a medical history of severe asthma and was also on HIV pre-exposure prophylaxis. He underwent treatment for mpox infection and syphilis, which resulted in a positive response. The suppressed antibody response was believed to be related to the prednisone treatment. [Extracted from the article]

A case report published in Reactions Weekly describes a 75-year-old man who developed diabetic ketoacidosis while receiving pembrolizumab treatment for malignant melanoma. The patient experienced osmotic symptoms and unintentional weight loss after the third treatment cycle, and was diagnosed with diabetic ketoacidosis during a pre-assessment clinic review for the fourth cycle. The man responded to treatment and was started on a basal-bolus insulin regimen. His HbA1c levels were high and the anti-glutamic acid decarboxylase (GAD) antibody test came back positive. [Extracted from the article]

Chemiluminescent enzyme immunoassay titer of anti-BP180NC16a antibody was 42.5 U/mL. A chemiluminescent enzyme immunoassay titers for the anti-BP180NC16a antibody revealed the highest value of 2060 U/mL on day 15, but reduced to 368 U/mL on day 30. Indirect immunofluorescence revealed serum IgG antibodies against the dermal-epidermal junction and IgG antibodies on the roof side of the split skin. [Extracted from the article]

He had been receiving heparin, and thrombocytopenia developed 8 days after the initiation of heparin treatment. Thus, et al. confirmatory functional assay based on heparin-induced platelet aggregation (i.e. platelet aggregation test) was performed, which also yielded a positive result. Thus, et al. confirmatory functional assay based on heparin-induced platelet aggregation (i.e. platelet aggregation test) was performed, which also yielded a positive result. [Extracted from the article]

The low COVID-19 immunoglobulin G titer and breakthrough COVID-19 infection were attributed to clozapine therapy. The low COVID-19 immunoglobulin G titer and breakthrough COVID-19 infection were attributed to clozapine therapy. [Extracted from the article]

After six months, his PLA2R antibody titer was 279 RU/mL with elevated serum creatinine. Following the fifth cycle of cyclophosphamide, his phospholipase A2 receptor (PLA2R) antibody titer increased to 417 RU/mL. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a case series, two male patients aged 33-36 years were described, who exhibited lack of efficacy with ciclosporin, cyclophosphamide, rituximab or prednisolone in treatment of membranous nephropathy (MN) [ I not all routes stated i ]. [Extracted from the article]

The woman, who had interstitial pneumonia with anti-SRP antibody positive polymyositis, started receiving treatment with prednisolone 5 mg/day, but her symptoms did not resolve. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An adult woman in her 40s [ I exact age not stated i ] exhibited lack of efficacy during treatment with prednisolone and immune globulin, had false negative antibody test during treatment with rituximab and developed I Strongylodiasis i hyperinfection syndrome during treatment with prednisolone and rituximab for anti-signal recognition particle (SRP) antibody positive polymyositis and interstitial pneumonia [ I not all routes stated; time to reaction onsets not stated i ]. [Extracted from the article]

Muscle biopsy revealed perifascicular atrophy with scattered fiber necrosis and upregulation of MHC-1, findings consistent with JDM. Childhood Myositis Assessment Scale (CMAS) showed 11/52 points with severe limb muscle atrophy. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 16-year-old boy exhibited lack of efficacy with azathioprine, while being treated for juvenile dermatomyositis (JDM) [ I route and dosage not stated i ]. [Extracted from the article]

Direct resolution immunofluorescence from perilesional skin revealed intercellular deposition of IgG antibodies and C3 realizing a honeycomb-like pattern, which confirmed the diagnosis of PV. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 72-year-old man developed pemphigus vulgaris (PV) during treatment with the tozinameran vaccine. Histopathology from the bullous lesion showed a suprabasal blister with acantholysis in the lower epidermal layers and occasional lymphocytes. [Extracted from the article]

Until postoperative day 5, the serum creatinine level was 1.0 mg/dL and the ABO antibody titer was 1:16. The serum creatinine level peaked at 5.7 mg/dL and decreased to 1.2 mg/dL at the end of treatment, and the ABO antibody titer increased to 1:64 and subsequently decreased to 1:16 after treatment. Despite the start of treatment, the serum creatinine level increased to 4.5 mg/dL and the ABO antibody titer was 1:32 (lack of efficacy). [Extracted from the article]